Teva   4Q Revenues: $5.2 billion (-5%) 4Q Earnings: $694 million (+84%) FY Revenues: $20.3 billion (flat) FY Earnings: $3.0 billion (+142%) Comments: Generic revenues were $2.5 billion in the quarter, down 8%. U.S. revenues were flat at $1.2 billion. European revenues were $759 million, down16%, with lower revenues in Germany, France and Spain. ROW revenues were $532 million, down 12%. API sales to third parties were $178 million, up 2%. Copaxone sales were $1.1 billion, down 2% in the quart...